




Engineering inducible cell lines for recombinant Adeno-






SUBMITTED TO THE FACULTY OF THE 











IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 





































 I am extremely grateful for the guidance and mentorship of my advisor, Professor 
Wei-Shou Hu. He has always made graduate student development his top priority, and 
never misses an opportunity to help us grow. I am constantly inspired by his commitment 
to collaborations, pioneering in the unknown, and prescient decision making. I have had a 
PhD experience that I could not have even dreamed of. Professor Hu has shaped me into 
the best scientist that I can be. 
 I want to express appreciation for all the great collaborators who have made our 
joint projects stimulating and rewarding. I thank Professor Daniel Schmidt, who helped us 
start our AAV work and guided our projects towards success and relevance in the field. I 
thank Professor Nikunj Somia for offering molecular biology insight into viral and 
mammalian gene expression engineering. I thank Professor Alon Herschhorn for our 
exciting work on developing stable cell lines for HIV and SARS-CoV-2 vaccine antigen 
production. And I would like to thank Professor Samira Azarin, Professor Ben Hackel, and 
Professor Nikunj Somia for taking the time to serve on my committee. 
Next, I would like to mention the members of the Hu group who have made my 
time at the University of Minnesota truly special. I really appreciate all that Dr. Arpan 
Bandyopadhyay was to me: teacher, mentor, friend. Huge thanks also to Thu Phan, who 
has endured the struggles of graduate school with me since day one. A special 
acknowledgment to Dr. Chris Stach, who taught me so much about molecular biology and 
vector design. I also want to thank all the members of the Hu group, past and present, for 
the support and great times we were able to share: Dr. Yonsil Park, Dr. Dong Seong Cho, 
Dr. David Chau, Dr. Tung Le, Dr. Conor O’Brien, Dr. Sofie O’Brien, Dr. Jen One, Dr. 
ii 
Kevin Ortiz-Rivera, Dr. Hansol Kim, Meghan McCann, Min Lu, Qian Ye, Yen-An Lu, and 
Janani Narayan. 
A special thanks to the undergraduates who have helped make our projects possible. 
I thank Eesha Irfanullah for contributing her brilliant mind to achieve our grand goals. I 
thank Morgan Soukup for contributing her relentless work ethic to the work at hand. I thank 
Marina Raabe and Noelle Schumacker for showing interest and initiative toward 
independent research. It has truly been an honor to be a supervisor and mentor to you all 
and one of the most rewarding aspects of my graduate school experience. 
 Lastly, I want to thank my family. I thank my parents and my sister for full and 
absolute support without adding any pressure. I want to thank my son for being my happy 
cheerleader. And I want to thank my wife for sustaining me, encouraging me, and making 




The recombinant adeno-associated virus (rAAV) gene therapy field has experienced 
landmark regulatory approvals in recent years by demonstrating high efficacy in treating 
monogenic diseases. There is therefore an immediate and increasing need for highly 
productive manufacturing platforms to generate large quantities of rAAV vectors. Current 
rAAV synthesis methods require multiple-component plasmid transfections or viral 
infections, which have increasing costs, variability, and technical challenges at large scales. 
To address the growing need for robust methods to produce and characterize rAAV vectors, 
we used synthetic biology tools to gain control over viral gene expression dynamics. First, 
we engineered a rAAV infectious titer assay cell which contains the AAV and helper genes 
necessary to replicate transduced genomes. Once exposed to small molecule inducers and 
a rAAV vector, the assay cell line performed similarly to the standard adenovirus (Ad) 
coinfection method in determining the infectious titer of the vector preparation. Omitting 
the use of Ad greatly simplifies the potency assay and reduces the variability of input 
reagents. Building on that success, we further engineered cells that not only have 
replicative capacity, but also packaging capacity and a latent copy of a rAAV genome. 
Small molecule induction allowed expression of the necessary viral genes to synthesize 
infectious rAAV vectors. The variation of inducer ratios enabled manipulation of vector 
quality, in terms of the fraction of DNA-containing particles. These synthetic cellular 
technologies address the needs of a reliable potency bioassay and a scalable and robust 
production platform for rAAV manufacturing. 
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Among vectors for human gene therapy, recombinant adeno-associated virus 
(rAAV) vectors are advantageous for their long-term efficacy, safety profile and serotype 
specificity. These therapies are able to dramatically change the lives of patients with 
previously untreatable diseases. The FDA approvals of Luxturna for retinal dystrophy in 
2017 and Zolgensma for spinal muscular atrophy in 2019 have generated much excitement 
about the future potential of this modality (He, Urip, Zhang, Ngan, & Feng, 2021). With 
the accelerating pace of new clinical trials, it is becoming increasingly important to have 
reliable bioassays to assess product functionality and innovations to make production more 
scalable and robust. With the new modality comes unique manufacturing challenges 
distinct from those faced with recombinant protein therapeutics such as monoclonal 
antibodies. Many of these difficulties can be overcome through the infusion of synthetic 
biology in vector manufacturing technology.  
Synthetic biology is a broad, expanding field consisting of many aspects. It involves 
the creation of new functionalities by learning from biological systems and engineering 
them towards a desired objective. Many recent advances have been in the areas of 
biomolecule sensing, synthetic genetic circuits, and biological elements responsive to 
external inputs (Kitada, DiAndreth, Teague, & Weiss, 2018). Inducible promoters activate 
gene transcription in response to inducers such as antibiotics, hormones, or even light 
(Kallunki, Barisic, Jäättelä, & Liu, 2019). Another mode of control is at the protein level, 
with many tools available for ligand-responsive protein degradation (T. Wu et al., 2020). 
These control tools, in conjunction with recent advances in transposon technology to easily 
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integrate large, multi-gene cassettes into mammalian cells (Balasubramanian, Wurm, & 
Hacker, 2016), create many opportunities to reinvent complex cellular systems. 
Viral replication and packaging are complex processes in mammalian cells. They 
involve a multitude of viral and host factors which enhance or mitigate one another. The 
ultimate goal of a wild-type virus is to make more progeny virions, often completely 
overtaking the host cell and causing cell death. Viral vector manufacturing takes this 
complex process and perturbs it away from its optimum by separating vector components 
from viral genes. It is not surprising then that vector titer, quality and potency are 
diminished compared to the wild-type virus (Zeltner, Kohlbrenner, Clément, Weber, & 
Linden, 2010). Synthetic biology can be the tool used to push the system back closer to its 
optimal functioning point. Further, the tendency of viruses to kill their host cells requires 
their genes to be controlled if host cells stably harboring viral genes are desired. 
1.1 Thesis organization 
This thesis represents the application of synthetic biology to innovate processes in 
rAAV manufacturing. Chapter 2 details the construction of a replication-competent cell 
line that can amplify transduced genomes and thereby enable sensitive readout of a vector’s 
potency. Chapter 3 details the construction of an exclusively inducible producer cell line 
which can generate infectious rAAV and enables manipulation of full particle content. 
Chapter 4 summarizes the work and provides directions for further development of the 
technology. In addition, the addendum, also called chapter 5, provides additional 
information into innovations in cell line development for discovering the most favorable 
epigenetic landing spots for transgene integration. 
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2 Development of an Inducible, Replication-Competent Assay Cell 
Line for Titration of Infectious Recombinant Adeno-Associated 
Virus Vectors 
Reproduced from: Lee, Z., Lu, M., Irfanullah, E., Soukup, M., Schmidt, D., Hu, W. 
Development of an Inducible, Replication-Competent Assay Cell Line for Titration of 
Infectious Recombinant Adeno-Associated Virus Vectors. (In preparation) 
 
2.1 Summary 
An important quality attribute of a recombinant Adeno-Associated Virus (rAAV) 
as a therapeutic vector is its infectious titer. Current infectious titer assays mostly rely on 
coinfection of rAAV with a helper virus such as adenovirus, which requires helper virus 
preparation and introduces additional variability. Here we describe a stable infectious titer 
assay cell line into which was integrated the coding sequences for AAV Rep68 and 
adenovirus E4orf6 and DNA Binding Protein (DBP) under the control of inducible 
promoters. The Rep68 protein expression was further modulated by a ligand-responsive 
destabilization domain. In parallel assays the cell line gave comparable titer to that obtained 
using a classical adenovirus coinfection method. The cell line was also used to titer vectors 
of multiple AAV serotypes. This cell line has the potential to serve as an effective and 
robust tool for product quality evaluation. 
2.2 Introduction 
Infectious titer is a critical indicator of the potency of a gene delivery product and 
is one of the most important quality attributes of a rAAV vector. But rAAV therapies are 
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typically dosed based on physical titer, in vector genomes per mL (vg/mL). Another 
measure often used to quantify rAAV is the total particle titer, measured in capsids per mL. 
Since there is not a universal relationship among physical titer, infectious titer, and total 
particle titer, it is crucial to characterize the ratios between them. Achieving a particle-to-
infectious unit ratio close to unity, which has been observed with wild-type AAV, 
represents the optimal scenario for a gene therapy vector (Zeltner et al., 2010). Yet for 
rAAV it was reported that the ratio between genome containing particles and infectious 
particles, called infectivity, was highly variable between production methods (Gao et al., 
1998). In addition, different production platforms yield varying ratios of genomes to 
capsids, also called the full-to-empty particle ratio (Merten, 2016). The vector genome 
copy can be measured by quantitative PCR (Werling, Satkunanathan, Thorpe, & Zhao, 
2015), while the total particle concentration can be measured by ELISA of capsid proteins 
(D. Grimm et al., 1999). Both are easily carried out in a typical laboratory.  
The infectious titer, in contrast, is commonly assessed using coinfection with a 
helper virus such as adenovirus (Ad) to provide helper functions for transduction and/or 
replication. For example, the replicative center assay (RCA) infects stable rep/cap-
expressing HeLa cells with rAAV and Ad, then transfers cells onto a nylon membrane and 
finally detects replicated rAAV genomes by fluorescent or radiolabeled probes (Salvetti et 
al., 1998; Zolotukhin et al., 1999). In another method, rep/cap-expressing HeLa cells 
seeded in a 96-well plate are infected with replicated dilutions of rAAV along with 
adenovirus, and the wells are assayed for vector genome replication by qPCR (Lock et al., 
2010; Zhen, Espinoza, Bleu, Sommer, & Wright, 2004). The theoretical dilution at which 
half of the replicates would be replication-positive is used to calculate the 50% tissue 
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culture infective dose (TCID50). Infectious titer can also be measured by  observing the 
number of cells expressing transgene after coinfection of rAAV with adenovirus (Xiao, Li, 
& Samulski, 1998). We will use the common notation that genome-detecting assays are 
reported in infectious units (IU) and transgene-detecting assays are reported in transducing 
units (TU). 
Ad coinfection requires additional Ad stock production and characterization. 
Coinfection methods may also introduce the potential bias of adenovirus-mediated 
endosomal disruption (François et al., 2018), which would result in over-estimation of 
rAAV infectious titer. As a complex bioreagent, Ad is a contributor to assay variability. 
The infectious titer assays already showed high variability in performance, especially 
between different characterization sites (Lock et al., 2010). A more robust infectious titer 
assay, preferably without using helper virus coinfection, will be welcome. 
AAV genome replication utilizes host cellular DNA replication machinery, but also 
relies on a subset of its own genes and some Ad genes. The large Rep78 or Rep68 protein 
processes AAV ITRs to unwind and create necessary nicks which are used to initiate the 
replication of AAV genomes (Gonçalves, 2005; Stracker et al., 2004).  The adenovirus 
DNA binding protein (DBP) binds to single-stranded genomes and enhances replication 
processivity (Ward, Dean, O'Donnell, & Berns, 1998), making it a requirement for efficient 
AAV replication (Matsushita et al., 1998). The E4orf6 protein of Ad mediates second-
strand synthesis of AAV genomes (Ferrari, Samulski, Shenk, & Samulski, 1996), a critical 
step in converting AAV genomes to double-stranded forms for transcription and DNA 
replication. 
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Previous attempts at generating stable cell lines expressing AAV and Ad genes have 
been hindered by the cytotoxicity of the AAV rep gene products (Qiao, Wang, Zhu, Li, & 
Xiao, 2002; Schmidt, Afione, & Kotin, 2000) and the Ad E2A and E4 gene products (Qiao, 
Li, Skold, Zhang, & Xiao, 2002). Our approach uses synthetic, inducible promoters to 
control the expression of AAV replication and Ad helper genes. We show that controlled 
expression of these genes supports efficient AAV genome replication for high infectious 
titer assay sensitivity. 
2.3 Methods 
2.3.1 Vector construct 
The replication module consists of rep and helper genes controlled by inducible 
promoters and the necessary transactivators. Under control of the GeneSwitchTM promoter 
(Invitrogen) were the adenovirus E4orf6 and DNA binding protein (DBP) sequences linked 
by the P2A self-cleaving peptide. The GeneSwitchTM transactivator (GSTA) transcriptional 
unit was included from the pSwitch vector (Invitrogen). Under control of the TetON 
promoter (Clontech) was the DD-mCherry-Rep68 fusion protein sequence, DD 
representing the mutant FKBP12 destabilization domain (Takara Bio Inc.). The final 
transcriptional unit included the reverse tetracycline transactivator (rtTA3) linked to the 
hygromycin-resistance protein sequence by the T2A self-cleaving peptide. All four 
transcriptional units were assembled into a piggyBac transposon vector (ATUM). 
2.3.2 Cell culture and transfection 
HEK293 cells (Cell Biolabs, Inc.) were cultured in Dulbecco's Modified Eagle 
Medium (Gibco) supplemented with 10% Fetal Bovine Serum (Gibco) and antibiotic-
antimycotic (Gibco). For assay cell construction, cells were transfected with an equal 
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amount of replication module plasmid and Leap-In transposase mRNA (ATUM) using 
Lipofectamine 3000 (Invitrogen). Transfected cells were cultured in media containing 200 
µg/mL Hygromycin B (Millipore Sigma) for two weeks to obtain a stable cell pool. The 
pool was seeded into 96-well plates at a dilution of 0.5 cells per well to obtain single cell 
clones. Each well was visually inspected under a microscope to ensure cells were derived 
from a single cell. Clones were expanded and cryopreserved.  
Triple transfection of pAAV-CAG-GFP (Addgene #37825), pHelper (Cell Biolabs, 
Inc.) and pAAV-RC2 (Cell Biolabs, Inc.) was conducted on HEK293 cells to generate 
rAAV2-GFP. Cells were lysed by three freeze-thaw cycles (-80°C/37°C) and treated with 
benzonase to result in a crude preparation. Purified vectors of AAV serotypes 2, 6, and 8 
were generated using the same pAAV-CAG-GFP plasmid by the University of Minnesota 
Viral Vector and Cloning Core. Viral vectors were purified with sucrose cushion 
ultracentrifugation resulting in titers ranging from 1.13 × 1012 to 8.69 × 1013 vg/mL. 
2.3.3 Flow cytometry assays 
RM4 cells were seeded at 1.5 × 105 cells per 24-well in basal media with 5 µg/mL 
doxycycline and 10 nM mifepristone. Varying dilutions of rAAV2-GFP were added to the 
wells the following day. After a two-day incubation period, cells were detached and 
analyzed on a BD LSR II flow cytometer for GFP fluorescence. For immunofluorescence 
detection of GFP expression, detached cells were fixed with 4% paraformaldehyde, 
permeabilized with 0.2% Triton X-100, incubated with mouse anti-GFP (Sigma G6539), 
then incubated with goat anti-mouse F(ab’)2 fragment, Alexa Fluor 647 conjugate 
(Invitrogen A-21237). Then cells were analyzed on a BD LSR II flow cytometer for Alexa 
Fluor 647 fluorescence. 
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2.3.4 Infectious titer plate assay 
The plate assay for infectious titer used quantitative PCR-based detection of 
replication events. Cells were seeded at 2.6 × 104 cells per 96-well and induced with 5 
µg/mL doxycycline and 10 nM mifepristone. Varying dilutions of rAAV2-GFP stock 
suspension were added to the wells in replicates of ten the following day. After a two-day 
incubation period, cellular DNA was harvested by QuickExtractTM solution (Lucigen) and 
quantitative PCR was run using primers against GFP. The mean cycle number and standard 
deviation of ten uninfected wells were used to define the negative range, and wells with 
cycle numbers three standard deviations below that mean were considered positive (Zhen 
et al., 2004). The Spearman-Kärber method was used to determine the 50% tissue culture 
infective dose, TCID50 (Kärber, 1931; Ramakrishnan, 2016). 
2.4 Results 
2.4.1 Infectious titer assay development 
The assay cell line, RM4, was constructed by integrating the replication module 
construct into HEK293 cells (Figure 2-1A) and screening among several single cell clones 
(Figure 2-2). Induction by mifepristone activates the GeneSwitchTM promoter, resulting in 
transcription of the Ad E4orf6 and DBP coding sequences. Induction by doxycycline 
activates the TetON promoter, resulting in transcription of the DD-mCherry-Rep68 fusion 
protein. DD is a mutant FKBP12 destabilization domain which upon tagging to a protein 
marks the protein for degradation unless stabilized by the Shield1 ligand (Banaszynski, 
Chen, Maynard-Smith, Ooi, & Wandless, 2006). Tagging Rep68 with DD and placing it 
under TetOn inducible promoter control minimized its possible cytotoxic effects. 
Transduction of rAAV2-GFP into uninduced RM4 cells resulted in only a few cells 
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expressing GFP, and the fluorescence intensity was low (Figure 2-1B). In contrast, RM4 
cells induced to express Rep68 and helper proteins were able to support the replication of 
exogenously transduced rAAV genomes and express the cargo GFP proteins. This was 
evident by strong GFP expression in many RM4 cells transduced with rAAV2-GFP 
particles (Figure 2-1C). 
 
Figure 2-1: Design and construction of an inducible rAAV assay cell line.(A) Replication-
competent cell line conceptual schematic showing high vector protein expression upon 
transduction. Inset shows integrated construct design with its inducible elements. (B) GFP 
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fluorescence image of RM4 cells transduced with rAAV2-GFP without induction. (C) GFP 
fluorescence image of RM4 cells transduced with rAAV2-GFP with doxycycline and 
mifepristone induction. (D) Relative infectious titer of RM4 cells upon transduction with 
rAAV2-GFP and induced with permutations of three molecules of interest. All values 
relative to apparent titer using uninduced cells. Data represents mean and standard 
deviation of four image-based cell counts. D=doxycycline, M=mifepristone, S=shield1. 
 
Figure 2-2: RM clone screening. (A) Round 1 screening of six R2 clones by adding a fixed 
amount of virus to induced cells. Transduction events counted by ImageJ. (B) Round 2 
screening, comparing the two best clones with the pool under controlled seeding density. 
Data represents mean and standard deviation of three independent experiments. 
Significance assessed by Welch’s t-test. **p<0.01, ***p<10-5. Clone 4 performed much 
better than the pool. 
The induction conditions strongly affected the number of transduced cells. Without 
any inducers, few cells were GFP positive. Inducing with both doxycycline and 
mifepristone gave the highest number of transduced cells, while moderate results were seen 
with doxycycline or mifepristone alone (Figure 2-1D). In all subsequent experiments RM4 
cells were induced with doxycycline and mifepristone. In all combinations of inducers, 
stabilizing Rep68 with Shield1 reduced the apparent titer compared to the case without 
Shield1. This is consistent with an earlier finding that reduction of large rep protein 
expression enhanced AAV replication (Li, Samulski, & Xiao, 1997).  
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2.4.2 Assay cell line benchmarking using flow cytometry 
Infectious titration of rAAV using RM4 cells was benchmarked against the 
traditional method of Ad coinfection. Flow cytometry measurement showed that the two 
assays gave similar fractions of GFP-positive cells (Figure 2-3A). A small fraction of cells 
in the RM4 assay had a very high, near saturation level of GFP expression, which was not 
seen in the Ad coinfection assay, likely due to viral genome amplification occurring in 
RM4 cells. The apparent titer of the rAAV2-GFP viral prep calculated from the fraction of 
GFP-positive cells was very similar between the RM4 assay (5.59 ± 0.15 × 108 TU/mL) 
and Ad coinfection assay (6.66 ± 0.16 × 108 TU/mL) (Figure 2-3B).  
 
Figure 2-3: Benchmarking apparent infectious titer of RM4 cells with a traditional method. 
(A) Flow cytometry population histograms of GFP-intensity for HEK293 cells coinfected 
with adenovirus and induced RM4 cells. The blue curve represents cells transduced with 
rAAV2-GFP, and the red curve represents untransduced cells. (B) Apparent infectious titer 
by adenovirus infection or RM4 clone, measured by GFP. Data represents mean and 
standard deviation of three replicates. (C) Flow cytometry population histograms of Alexa 
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Fluor 647-intensity for immunostained HEK293 cells coinfected with adenovirus or 
induced RM4 cells. The blue curve represents cells transduced with rAAV2-GFP, and the 
red curve represents untransduced cells. (D) Apparent infectious titer by adenovirus 
infection or RM4 clone, measured by Alexa Fluor 647-tagged Anti-GFP antibody. Data 
represents mean and standard deviation of three replicates. 
In clinical applications, the payload gene will not be a reporter but a therapeutic 
protein. Immunostaining of the cargo protein was used to detect the transduction of rAAV. 
GFP protein in rAAV2-GFP-infected RM4 cells was detected by immunostaining with a 
mouse anti-GFP antibody and an Alexa Fluor 647-tagged anti-mouse secondary antibody 
and benchmarked against the Ad coinfection assay with the same immunostaining 
procedure. Flow cytometry measurement of immunostained RM4 cells and Ad coinfected 
cells gave similar fractions of Alexa Fluor 647-positive cells (Figure 2-3C). As with the 
GFP-based method, RM4 cells showed a subpopulation with very high magnitude of Alexa 
Fluor 647 fluorescence. Again, the RM4 assay gave an apparent infectious titer of the 
rAAV2-GFP preparation (5.12 ± 0.26 × 108 TU/mL) very similar to one obtained by the 
Ad coinfection assay (6.01 ± 0.14 × 108 TU/mL) (Figure 2-3D). 
2.4.3 Plate assay for infectious titration 
We next compared fluorescence-based assays using RM4 with a qPCR-based 
TCID50 assay. For the TCID50 assay, rows of ten wells of induced RM4 cells were 
transduced with dilutions of rAAV2-GFP such that at a limiting dilution, wells will 
probabilistically receive one (or more) infectious units, or none at all. Replicated genomes 
were detected using qPCR, and the positive wells detected were shown as a plate-view map 
(Figure 2-4A). The percent positive wells from each row were plotted against the dilution 
factor, and the Spearman-Kärber method was used to calculate the infectious titer as 6.0 ± 
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1.8 × 108 TCID50/mL across three replicates (Figure 2-4B). The TCID50 assay titer was 
thus similar to the GFP fluorescence and immunofluorescence assay titers. 
 
Figure 2-4: TCID50 method of assaying infectious titer using RM4 cell line. (A) Visual 
plate view of a representative limiting-dilution TCID50 infectious titer assay. Green squares 
indicate wells which were positive for vector genomes via quantitative PCR. Experiment 
was performed on RM4 cells in 96-wells. (B) Calculation of apparent titer according to the 
Karber method. 
2.4.4 rAAV Infectivity 
Two independent preparations of the same GFP-bearing genome were available to 
compare infectivity ratios. Vector genome titers were measured using qPCR and the ratio 
to infectious titer measured by GFP fluorescence was calculated to be the infectivity. One 
preparation, which represented a relatively crude extraction of rAAV2-GFP vector, had a 
VG:TU ratio of 175 (Table 2-1). Another preparation was purified by ultracentrifugation 
and had a VG:TU ratio of 86,447 (Table 2-1).  
Table 2-1: Infectivity of two rAAV2 preparations. The VG:TU infectivity ratio of two 
rAAV2 preparations are shown here. The first preparation was a crude preparation of 
rAAV2-GFP generated in house, used for Figure 1. The second preparation was a highly 
purified vector used for Figures 2 and 3. 
rAAV2-GFP preparation Infectivity (VG:TU) 
1 175 ± 25 
2 86,447 ± 29,193 
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2.4.5 Titration of different AAV serotypes 
The rAAV virus stocks used in the assays described above were of serotype 2. 
HEK293 cells, from which RM4 were derived, express surface receptors for other AAV 
serotypes including serotypes 6 and 8 which are commonly used in gene therapy studies. 
RM4 cells were used to determine the infectious titer of rAAV-GFP of serotypes 6 and 8 
(Table 2-2). As with serotype 2, assessment of serotypes 6 and 8 were comparable between 
RM4 assays and the Ad coinfection assays. 
Table 2-2: Infectious titers of additional serotypes. Infectious titers of rAAV6 and rAAV8 
harboring a GFP transgene, measured using flow cytometry analysis of HEK293 cells 
coinfected with Ad and RM4 assay cells. Data represents mean ± standard deviation of 
three replicates. 
 Apparent Infectious Titer (TU/mL) 
AAV Serotype 293+Ad RM4 
AAV6 9.24 ± 0.21 × 106 1.06 ± 0.05 × 107 
AAV8 1.26 ± 0.17 × 107 1.66 ± 0.21 × 107 
 
2.5 Discussion 
Infectivity is a critical determinant of the functionality of an rAAV vector for gene 
therapy. A robust quantification method of infectivity is important to manufacturing 
process optimization and characterization. We constructed an rAAV assay cell line, RM4, 
to enable a rapid and sensitive measurement of infectious titer. These cells expressed AAV 
replication and Ad helper elements upon induction with small molecules to allow them to 
replicate the vector genome upon infection of rAAV.  The amplification of infected rAAV 
genomes allowed for sensitive detection of cargo protein expression or presence of vector 
genomes and easy enumeration of rAAV-infected cells for titer quantification. The 
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infectious titers determined using RM4 was comparable to those determined using the 
conventional adenovirus coinfection method for serotypes 2, 6, and 8. The RM4 based titer 
assay eliminates helper virus from the protocol making the method simpler, safer and less 
susceptible to variability in helper virus preparation. 
Using flow cytometry, we quantified the fraction of transduced RM4 cells or Ad 
coinfected HEK293 cells as indicated by GFP fluorescence or immunostaining of GFP. 
Our flow cytometry measurements had good intra-assay repeatability between replicates, 
indicated by relative standard deviations below 6%. RM4 cells reported infectious titers 
16% and 15% lower than the classical Ad coinfection method for GFP fluorescence and 
immunofluorescence assays, respectively. Although the differences appeared significant, 
bioassays typically have high degrees of intermediate and inter-assay variability, 
corresponding to assays conducted in separate runs and separate facilities, respectively (J. 
W. Lee et al., 2006). Bioassays for potency especially have high levels of overall variability, 
with standard deviation reported up to 101% of the mean in rAAV2 transgene expression 
assays for infectious titer (Lock et al., 2010). Therefore, the slightly lower infectious titer 
with RM4 cells compared to Ad coinfected cells is relatively minor compared to range of 
the expected bioassay variability. Nonetheless, minor differences may have been 
influenced by the previously mentioned endosomal disruption mediated by Ad which can 
lead to over-estimation of rAAV titers (François et al., 2018). Another possible 
contributing factor of the difference could have been a cellular host response. rAAV 
replication is known to trigger DNA damage response proteins such as ATM (Schwartz, 
Carson, Schuberth, & Weitzman, 2009), which in turn inhibit rAAV transduction (Zentilin, 
Marcello, & Giacca, 2001). Despite these known phenomena potentially driving 
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differences in titer, the RM4 cells obtained a final titer relatively similar to the current 
standard method of Ad coinfection, demonstrating their utility. 
Immunostained titers were measured to be slightly lower than the respective GFP 
titers using the corresponding assay cells. These slight differences could have been the 
result of non-specific binding of primary or secondary antibodies in the untransduced 
controls (see Figure 2-5), which may have increased the gating threshold for calling 
positive events. However, these differences were less than 10%, which is similar to sources 
of variability such as cell counting uncertainty (Cadena-Herrera et al., 2015). 
 
Figure 2-5: Two-dimensional cytograms of immunostained assay cells. Flow cytometry 
results showing Alexa Fluor 647 (anti-GFP) signal and GFP signal of adenovirus-
coinfected HEK293 cells (left pair) and doxycycline- and mifepristone-induced RM4 cells 
(right pair). Cells transduced with rAAV2-GFP (left of pair) are shown along with their 
untransduced controls (right of pair). Most Alexa Fluor 647- and GFP-positive cells were 
also positive for the other, lying completely on the diagonal region of the plot. This 
demonstrates any cargo gene encoding a protein of interest can be assayed using these cells 
with a simple immunostaining assay. 
RM4 cells were also used in a TCID50 quantitative PCR-based assay. Using the 
same rAAV sample, remarkable consistency was observed between flow cytometry-based 
and qPCR-based assays despite the methods being completely orthogonal. The final ratio 
of TCID50-derived and GFP fluorescence-based titers yielded a TCID50:TU ratio of 1.07. 
The TCID50:TU ratio close to unity contrasts with previous studies which performed both 
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types of assays and found a TCID50:TU ratio of 8.6 (Lock et al., 2010) and 125 (François 
et al., 2018). The cited ratios may have been higher because of their use of adenovirus 
coinfection, longer assay time (72 hours), and host cell origin (HeLa). Yet we believe the 
good agreement between flow cytometry-based titers and TCID50 titer is a strength, 
demonstrating the consistency and reliability of a stable, inducible cell line. 
Using the RM4 assay cell line, the infectivity of two different AAV preparations 
were found to be in between 102 and 105 VG:TU (Table 2-1), which is in the range reported 
previously using HEK293 assay cells (Gao et al., 1998; Mohiuddin et al., 2005).  It was 
encouraging that the RM4 assay cells enabled assessment of vector potencies over nearly 
three orders of magnitude. One potential reason for the difference in rAAV potency 
between preparations could be different degrees of aggregation, which have been observed 
in some rAAV vectors following DNase treatment (Dobnik et al., 2019). In addition, post-
translational modifications to AAV capsids and vector genome methylation were observed 
to vary based on rAAV production platform (Rumachik et al., 2020). Finally, the method 
of purification has also been shown to impact infectivity (El Andari & Grimm, 2021). 
The RM4 assay cells were also shown to be effective at measuring infectious titers 
of rAAV serotypes 2, 6 and 8. It was reported that HEK293 cells are not efficiently 
transduced by serotypes 4, 5, and 9 (Dirk Grimm et al., 2008). A previous attempt to 
increase pan-serotype infectivity by overexpressing the “universal” AAVR receptor 
resulted in improvement in only some serotypes (McDougald et al., 2019). It may be of 
interest to increase the sensitivity of the assay cell line toward inefficient serotypes by 
expressing specific receptors or receptor processing genes. Those cells would be an 
important step towards a universal infectious titer assay cell line. 
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2.6 Conclusion 
Until now, infectious titer assays have required adenovirus coinfection, representing 
tedious and advanced laboratory techniques. These RM4 assay cells allow for rapid and 
sensitive titration of viral particles using induction with small molecules. Doxycycline and 
mifepristone are inexpensive inducers which come with much lower source variability than 
a complex biological agent such as adenovirus. The cell line represents a product of the 
growing demand for high quality assays to assess vector product functionality. 
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3 Construction of a rAAV Producer Cell Line through Synthetic 
Biology 
Reproduced from: Lee, Z., Lu, M., Irfanullah, E., Soukup, M., Hu, W. 
Construction of a rAAV Producer Cell Line through Synthetic Biology. (In preparation) 
 
Z. Lee performed producer cell construction and characterization. M. Lu performed 




The complexity of recombinant adeno-associated viruses (rAAV) poses a challenge 
to the creation of stable cell lines as a scalable platform for rAAV production. Here we 
describe a template for a transfection-free, helper virus-free rAAV producer cell line using 
synthetic biology. Three modules were integrated into HEK293 cells including an rAAV 
genome and multiple inducible promoters controlling all necessary AAV Rep, capsid, and 
helper coding sequences. The synthetic cell line yielded roughly 500 vector genomes per 
cell and was stable for at least 30 generations. Independent control over replication and 
packaging genes allowed for manipulation of the full capsid content, reaching up to 73%. 
Robust rAAV genome amplification was observed, indicating potential areas of 
improvement in capsid protein expression. The achievement represents an approach that 
enables highly controllable production of rAAV at large scale. 
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3.2 Introduction 
 Recombinant AAV production is much more complex than traditional biologics 
manufacturing. First, the product is a nanoparticle consisting of roughly sixty capsid 
proteins at a 1:1:10 ratio of VP1:VP2:VP3 proteins (Gonçalves, 2005) encapsidating a 
single-stranded DNA molecule of up to 5 kilobases in size (Z. Wu, Yang, & Colosi, 2010). 
Second, viral replication involves the interaction of multiple viral and host factors which 
accelerate cell death. The large rep proteins Rep78 or Rep68 nick AAV genomes in the 
Internal Terminal Repeats (ITRs) (Tullis Gregory & Shenk, 2000), facilitating replication 
by the host cell DNA polymerase. Adenoviral single-stranded DNA-Binding Protein (DBP) 
improves processivity of DNA replication (Ward et al., 1998) and is also involved in 
forming sub-nuclear viral replication centers (Hidalgo et al., 2016; Weitzman, Fisher, & 
Wilson, 1996). Adenoviral E4orf6 protein has many functions, including export of viral 
mRNA from the nucleus, blockage of p53 activity, and stimulation of AAV second-strand 
synthesis (Leppard, 1997). Adenoviral VA RNA are non-coding RNAs which bind to and 
inactivate PKR, subduing the cellular anti-viral response of protein synthesis arrest 
(Vachon & Conn, 2016). Capsid assembly is catalyzed by the Assembly Activating Protein 
(AAP) and localized to the nucleolus (Sonntag, Schmidt, & Kleinschmidt, 2010). Finally, 
the small rep proteins Rep52 or Rep40 are required for insertion of single-stranded AAV 
genomes into pre-formed capsids (King, Dubielzig, Grimm, & Kleinschmidt, 2001). More 
viral factors are continuously being discovered, such as the membrane-associated assembly 
protein (MAAP) which add further complexity to the viral life cycle (Ogden, Kelsic, Sinai, 
& Church, 2019). The concert of biological reactions complicate efforts to make 
manufacturing platforms efficient yet consistent. 
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 The most common platform for rAAV vector generation is the transfection of 
plasmids encoding the therapeutic cassette flanked by AAV ITRs, the AAV rep and cap 
genes, and adenovirus helper genes E2A, E4, and VA RNA (Clément & Grieger, 2016). This 
method generates vectors in a short timeline, but has limitations at large scales, including 
GMP plasmid preparation, transfection efficiency, and reagent cytotoxicity (Srivastava, 
Mallela, Deorkar, & Brophy, 2021). Alternative technologies typically integrate some of 
the necessary components into the cellular genome or helpervirus genome. Stable 
integration of AAV rep/cap and rAAV genome into HeLa (Chadeuf et al., 2000; Clark, 
Voulgaropoulou, Fraley, & Johnson, 1995) and A549 (Farson et al., 2004) cells resulted in 
clones which produced rAAV upon infection with adenovirus. Herpes simplex virus (HSV) 
was identified as an alternative helpervirus, inspiring a production system where 
suspension Baby Hamster Kidney cells are co-infected with a recombinant HSV containing 
the rAAV genome and another recombinant HSV containing AAV rep/cap genes (Thomas 
et al., 2009). In the OneBac system, stable AAV rep and cap sequences in Sf9 insect cells 
are induced upon infection with a recombinant baculovirus which harbors the rAAV 
genome (Mietzsch et al., 2013). However, these methods possess other challenges, such as 
helpervirus removal in purification (Clément, Knop, & Byrne, 2009), GMP helpervirus 
preparation (Wright, 2008) and helpervirus genetic stability (Kohlbrenner et al., 2005). 
 For decades the biologics industry has achieved great success by creating stable 
cell lines which can be cultured in suspension at high densities. The main barrier to achieve 
stable cell lines for AAV production has been the toxicity of rep (Schmidt, Afione, & Kotin 
Robert, 2000) and helper genes (Qiao, Li, et al., 2002). The key to navigating around this 
challenge has been synthetic biology, which has seen much recent development especially 
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in mammalian applications. Many previous efforts have shown effective control of the 
most toxic protein, Rep78, using the dexamethasone-inducible mouse mammary tumor 
virus promoter (Hölscher et al., 1994), the heavy metal-inducible mouse metallothionein 
promoter (Yang, Chen, & Trempe, 1994), and the doxycycline-inducible Tet-On promoter 
(Chen, Clark, Chen, Schnepp, & Johnson, 2002). Similar promoters have been used to 
control Adenovirus helper proteins DBP and E4orf6 (Brough, Lizonova, Hsu, Kulesa, & 
Kovesdi, 1996; Kovesdi & Hedley, 2010). To control the levels of toxic Rep52 genes, a 
“dual splicing switch” was designed, representing a synthetic intron with a Cre-excisable 
array of polyadenylation signals (Qiao, Wang, et al., 2002). An early effort to integrate all 
necessary components for AAV production resulted in cell lines which were not stable 
(Qiao, Li, et al., 2002). Recently, a fully inducible rep, cap, and Helper system has been 
developed, demonstrating the necessity of synthetic biology in stable AAV production 
(Coronel et al., 2021). 
 Being able to produce rAAV is not the only objective for a stable cell line. The 
resulting platform should generate high quality vectors, especially in the aspect of full 
capsid content. Patient immune responses pose a great challenge for rAAV therapies 
(Manno et al., 2006; Mingozzi & High, 2013) and having excess empty capsids will only 
increase the antigenic load without delivering the therapeutic payload. It has traditionally 
been the burden of downstream purification efforts to separate the full capsids from empty 
capsids. Ultracentrifugation methods using CsCl or iodixanol gradients are effective in 
separation based on density differences but are not easy to use at large scale (El Andari & 
Grimm, 2021). Ion exchange chromatography is a more scalable method that can 
efficiently separate full particles from empty particles based on isoelectric point (Tomono 
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et al., 2018). Nevertheless, low full capsid content and variability between batches put 
additional burden on downstream processes. 
 In this study, we constructed stable producer and packaging cell lines of rAAV 
using synthetic biology tools. We were able to demonstrate control over viral genes and 
subsequently rAAV titer and full capsid content. This novel strategy enables scalable 
manufacturing of rAAV with control over vector quality in the production phase. 
3.3 Methods 
3.3.1 Vector Design 
 The rAAV2-GFP genome from pAAV-CAG-GFP (Addgene #37825) was cloned 
into a piggyBac transposon backbone (ATUM, Inc.) with a puromycin resistance gene 
driven by a phosphoglycerate kinase promoter, yielding the rAAV genome module. AAV 
Rep68 sequence was synthesized by Integrated DNA Technologies and the Rep40 start 
codon ATG was mutated to GGG by PCR, as previously reported (Chejanovsky & Carter, 
1989). Rep68 was tagged with mCherry and a mutant FKBP12 destabilization domain 
(Takara Bio) (Banaszynski et al., 2006). The resulting fusion protein was cloned 
downstream of the TetON promoter (Takara Bio). The adenovirus E4orf6 and DBP 
sequences were PCR amplified from the pHelper plasmid (Cell Biolabs, Inc.) and joined 
by a P2A linker. The resulting CDS was cloned downstream of the GeneSwitch promoter 
(ThermoFisher Scientific). The Rep68 and helper transcriptional units, as well as the 
GeneSwitch transactivator gene, were cloned into a piggyBac transposon backbone with a 
hygromycin resistance gene linked via T2A to the reverse Tet transactivator, yielding the 
replication module. AAV cap CDS was PCR amplified from pAAV-RC2 (Cell Biolabs, 
Inc.) and modified to omit the native intron and mutate the VP1 start codon to ACG, as 
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described previously, and termed VP123 (Urabe, Ding, & Kotin, 2002). The VP123 
sequence was linked to AAV Rep52 via the ECMV IRES and placed under the control of 
the CumateSwitch promoter (System Biosciences). The transcriptional unit was cloned into 
a piggyBac transposon backbone with a blasticidin resistance gene linked via T2A to the 
Cym Repressor, yielding the packaging module. 
3.3.2 Cell Culture 
 HEK293 cells (Cell Biolabs, Inc.) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM, Gibco) supplemented with 10% Fetal Bovine Serum (Gibco) and 1X 
antibiotic-antimycotic (Gibco). Stable cell lines were generated by co-transfection of 
transposon vectors with Leap-In transposase mRNA (ATUM, Inc.) at a 1:1 DNA:RNA 
ratio. After three days of outgrowth, cells were passaged into media containing 2 µg/mL 
puromycin (Invivogen), 200 µg/mL hygromycin B (MilliporeSigma), and/or 10 µg/mL 
blasticidin (Invivogen). After two weeks of selection, single-cell cloning was performed in 
96-wells by limiting dilution. RM4 infectious titer assay cells were previously developed 
(submitted manuscript) by integration of the replication module into HEK293 cells. 
Producer cell lines Pf3 and Pf6 were generated by integration of the genome, replication, 
and packaging modules into HEK293 cells. Packaging cell line RP6 was generated by 
integration of the packaging module into RM4 assay cells. 
 Infectious titer assays were conducted by seeding RM4 cells at 1.5 × 105 cells per 
24-well with 5 µg/mL doxycycline (Sigma Aldrich) and 10nM mifepristone (ThermoFisher 
Scientific). rAAV preparations were added to the cultures one day after seeding, and 
infectious titers were measured two days post transduction. For rAAV production via 
producer cells, cells were seeded at 3.75 × 105 cells per 6-well with 5 µg/mL doxycycline, 
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10nM mifepristone, and 30 µg/mL cumate (Sigma Aldrich), unless noted otherwise. Cells 
were harvested four days post seeding. For rAAV production via packaging cells, cells 
were seeded at 7.5 × 105 cells per 6-well with 5 µg/mL doxycycline, 10nM mifepristone, 
and 30 µg/mL cumate. One day post seeding, cells were transduced with seed rAAV2-GFP 
virus, and cells were harvested four days post seeding. Intracellular DNA and RNA were 
harvested using the Quick-DNA/RNA Miniprep (Zymo Research D7001) and quantified 
by qPCR and qRT-PCR using standard methods. 
3.3.3 rAAV Preparation and Characterization 
 Harvested cells were lysed by three cycles of freeze/thaw at -80°C/37°C and treated 
with ≥250 units/mL Benzonase (Millipore Sigma E1014) for one hour. Benzonase activity 
was quenched by adding 2mM EDTA, and cell debris was removed by centrifugation. For 
physical titration, proteinase K (Macherey-Nagel, 740506) was added to release DNA, and 
ssDNA was isolated by column purification (Zymo Research). Quantitative PCR was 
performed on purified genomes with pAAV-CAG-GFP as a reference standard using 
primers against the GFP coding sequence. Capsid titer was measured using an A20 
antibody ELISA kit (Progen PRATV). 
3.4 Results and Discussion 
To construct a rAAV producer cell line, three genetic modules were integrated into 
the genome of HEK293 cells: the rAAV genome, replication module, and packaging 
module (Figure 3-1A). The replication module consisted of adenovirus E4orf6 and DBP 
linked by P2A under the GeneSwitch promoter control and AAV Rep68 tagged by DD and 
mCherry under the TetON promoter control. The DD was a destabilization domain that 
could be stabilized upon the addition of the Shield1 ligand. Because Rep68 was suspected 
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to be the most cytotoxic viral factor, the design used both the DD and the TetON promoter, 
which showed the lowest degree of leaky expression (Figure 3-2). In the packaging module, 
intron-less AAV cap, called VP123, and AAV Rep52, were controlled by the 
CumateSwitch promoter. Since cap transcripts were known to be expressed at the highest 
levels (Mouw Matthew & Pintel David, 2000; Stutika et al., 2016), they were placed under 
the CumateSwitch promoter, which conferred the highest level of induced expression 
(Figure 3-2). Because it was reported that the sequence downstream of an IRES 
experiences attenuated translation (Mizuguchi, Xu, Ishii-Watabe, Uchida, & Hayakawa, 
2000), Rep52 was linked to VP123 via an IRES sequence since small Rep transcripts are 
not as highly abundant as cap transcripts (Mouw Matthew & Pintel David, 2000). The three 
vectors were stably integrated via piggyBac transposase into HEK293 cells using three 
separate selection markers. 
27 
 
Figure 3-1: Vector design and producer clone characterization. (A) A synthetic rAAV 
producer cell line and its three AAV genetic elements. GSTA denotes the GeneSwitch 
transactivator gene; rtTA3 denotes the reverse Tet transactivator gene; CymR denotes the 
Cym Repressor; DD denotes the Destabilization Domain. (B) GFP fluorescence images of 
infectious titer assay cells transduced with rAAV2-GFP produced by Pf3 or Pf6 clones. (C) 
Virus titer obtained through the induction of Pf3 and Pf6 cells. Physical titers, measured 
by qPCR, showing the mean and standard deviation of three qPCR wells. Infectious titers 
measured by flow cytometry analysis of rAAV-transduced assay cells. 
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Figure 3-2: Inducibility of viral transcripts in Pf3 and Pf6 producer cells. (A) Uninduced 
Pf3 and Pf6 transcript expression levels of viral genes and (B) fold-induction. 
Two producer cell clones, Pf3 and Pf6, were isolated. Upon induction, both clones 
were able to produce infectious rAAV vectors (Figure 3-1B), as evidenced by GFP 
fluorescence in RM4 infectious titer assay cells developed previously (manuscript in 
preparation). The physical titer, in vector genomes per mL, and the infectious titer, in 
transducing units per mL were measured for clones Pf3 and Pf6 (Figure 3-1C). Pf3 had 
higher titers, hence Pf3 was used in further experiments. Clonal differences may have 
arisen from variance in transcriptional activity of synthetic genes, which is influenced by 
the epigenomic contexts of transgene integration sites (Z. Lee, Raabe, & Hu, 2021), and 
transgene copy numbers (Joe Carver et al., 2020). In addition, clones could have had 
different levels of innate immune response factors which trigger inhibitory reactions to 
viral processes (Muhuri et al., 2021). 
The productivity of Pf3 cells was responsive to inducer concentrations. The 
infectious rAAV yield increased with increasing doxycycline concentration (Figure 3-3A) 
and increasing cumate concentration (Figure 3-3B). These results demonstrated a strong 
control over viral genes in the uninduced states, and robust induction of viral genes in the 
induced states (see also Figure 3-2). The ratio of the doxycycline and cumate 
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concentrations had an impact on the particle titer and the full capsid content (Figure 3-3C). 
At low doxycycline and high cumate levels, particle titers were high but full capsid contents 
were low. Conversely, with high doxycycline and low cumate levels, particle titers were 
low but full capsid content was high, approximately 73%. This demonstrated the ability to 
modulate full capsid content using independent control of viral genes. Using the triple 
transfection method, we obtained approximately 35% full capsid content. In a previous 
study, full capsid contents of multiple runs were below 20% (D. Grimm et al., 1999), while 
in another study, full capsid content was approximately 50% (Zeltner et al., 2010). It is 
clear that the full capsid content is highly variable and unpredictable, but by adjusting ratios 




Figure 3-3: Response of Pf3 cells to inducer concentrations. (A) Effect of doxycycline 
concentration on infectious rAAV yield, measured by infectious titer assay cells. The 
relative titer was in reference to the titer obtained with the highest doxycycline 
concentration. Mifepristone and cumate concentrations were kept at 10nM and 30µg/mL, 
respectively. Data represents mean and standard deviation of cell counts from twelve 
images. (B) Effect of cumate concentration on infectious rAAV yield, measured by 
infectious titer assay cells. The relative titer was in reference to the titer obtained with the 
highest cumate concentration. Data represents mean and standard deviation of cell counts 
from twelve images. (C) Effect of varying dox:cumate ratios on particle titer and full capsid 
content. Presented numbers for Dox and Cumate represent the actual concentration of the 
inducers used, in µg/mL. Data represents mean and standard deviation of three independent 
replicates. Significance assessed by Welch’s t-test in comparison to the 10:90 Dox:Cumate 
ratio condition. *p<0.05, **p<0.01, ns = not significant. 
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New technologies should be benchmarked against the current standard methods. To 
that aim, the specific physical and particle titers of Pf3 producer cells were compared to 
those values of the widely used triple-transfection method (Figure 3-4A). Both values in 
Pf3 cells (506 vg/cell and 703 capsids/cell) were roughly two orders of magnitude lower 
than the triple-transfection method. While specific titers may be lower, theoretically 
volumetric titers can be similar or higher due to recent advances in perfusion technology 
which allows cell densities up to 108 cells/mL (Schwarz et al., 2020). Still, there may be 
opportunities to further improve Pf3 or equivalent cells in terms of vector design and 
process optimization. When comparing gene expression between the two methods, Pf3 
cells had roughly 4-fold lower large Rep and DBP/E2A transcript levels but similar VP2/3 
levels, VP2/3 being the most important cap transcript isoform (Figure 3-4B). The VP2/3 
transcript levels being similar contrasted with the lower particle titer observed in Figure 
3-4A. A possibility is that protein levels in Pf3 did not reach the levels of triple transfection, 
or potentially there were enough proteins but a lack of assembly into capsid particles. 
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Figure 3-4: Comparison of Pf3 performance with triple transfection rAAV production 
method. (A) Specific physical (vector genomes per cell) and particle (capsids per cell) titers 
of triple transfection and Pf3 production methods. Data represents mean and standard 
deviation of replicate qPCR wells and capsid ELISA wells. Significance assessed by 
Welch’s t-test in comparison to the Triple Transfection condition. **p<0.01. (B) Transcript 
expression of viral genes at the end of production. Data represents mean and standard 
deviation of triplicate qPCR wells. (C) Total intracellular genomes (packaged and 
unpackaged) in uninduced and induced Pf3 cells. Data represents mean and standard 
deviation of triplicate qPCR wells. 
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One notable feature omitted from the synthetic cell lines that is usually present in 
the triple transfection production method was adenovirus VA RNA. Adenoviral VA RNAs 
have been reported to be expressed at extremely high levels (108 copies/cell) (Vachon & 
Conn, 2016) and they have been shown to induce the type I interferon innate immune 
response (Yamaguchi et al., 2010). Potential cytotoxicity was one reason why we chose to 
omit integration of VA RNA. Additionally, the target of VA RNA, PKR, is typically 
triggered by double-stranded RNA, which we thought would not be present at high levels 
in our synthetic cell lines due to the replacement of viral promoters with inducible 
promoters. The discrepancy between the capsid mRNA levels and capsid titers in Pf3 cells, 
may indicate a potential avenue for improvement in integrating the Ad VA RNA. 
Encouragingly, doxycycline-inducible expression of a VA RNA was previously shown to 
be feasible in a stable cell line (Machitani et al., 2011). 
To assess if replication could also be an explanation to the disparity in physical 
titers observed, the total intracellular genomes of Pf3 cells were measured in uninduced 
and induced states (Figure 3-4C). Uninduced copy numbers were low, representing the 
basal copy number of stably integrated rAAV genomes. Upon induction, genome copy 
number reached an excess of 104 genomes per cell, which was in the same order of 
magnitude as the triple transfection physical titers. Thus, it appears that the level of genome 
replication in Pf3 cells may not be the limiting factor despite the lower transcript levels of 
large Rep and helper genes seen in Figure 3-4B. This was consistent with the finding that 
reduced large Rep protein expression using an ACG inefficient start codon did not reduce 
titers but rather led to increased titers (Li et al., 1997). Pf3 producer cells and RP6 
packaging cells also showed reduced viral titers when Shield1 was added to stabilize Rep68, 
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suggesting that Rep68 protein levels were sufficient (data not shown). Thus, even though 
the capability to increase Rep68 concentrations was implemented in our design, it was kept 
in the destabilized state for improved rAAV production in all experiments presented. Yet 
as more knowledge is gained about the temporal requirements of large Rep proteins, the 
stabilizable control of Rep68 remains a tool which can be utilized to fine-tune protein levels 
for optimal rAAV production. 
Due to the cytotoxicity of Rep and Helper genes, assessment of the stability of the 
cell line was regarded as crucial. In commercial manufacturing, cells must be sufficiently 
stable in order to faithfully perform their functions after expansion from cryovials to large 
scale, high density bioreactors. Pf3 cells were passaged in selection media for 30 doublings 
and the physical titers were compared to the early generation of cells (Figure 3-5). The 
physical titer remained in the same range, and on a per-cell basis did not decrease over this 
time. This was encouraging to see that performance could be maintained through long-term 
culture. A previous study which aimed to integrate all AAV and helper components did not 
obtain stable cell lines presumably because of uncontrolled expression from E2A and E4 
(Qiao, Li, et al., 2002). A cell line constitutively expressing E2A has been documented 
(Zhou, O'Neal, Morral, & Beaudet, 1996), so the cytotoxic gene was likely E4. Taken 
together, it appears that at minimum, all presented AAV factors – large Rep, small Rep, 
and capsid proteins and Ad factor E4orf6 should have gene expression control in some 
form to obtain stable AAV producer cell lines. 
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Figure 3-5: Pf3 cell line stability. Physical titer and specific physical titer measured for Pf3 
cells induced at early and late generation numbers. Data represents mean and standard 
deviation of replicate qPCR wells. Significance assessed by Welch’s t-test in comparison 
to the 3 Doublings condition. ns = not significant. 
A variation of the rAAV producer cell line concept was that of a packaging cell 
line, which did not possess an integrated copy of the rAAV genome, but still contained the 
replication and packaging modules. In these cells, a rAAV genome could be supplied by 
seed virus infection or plasmid transfection (Figure 3-6A). A packaging cell clone, RP6, 
was induced and infected with seed rAAV2-GFP at 175 vg/cell to produce more virus. The 
resulting vectors were transduced into assay cells and successful transduction events were 
seen (Figure 3-6B). In contrast, very few GFP-positive assay cells were observed when 
HEK293 cells were used as a mock control. This confirmed that the vectors measured were 
a result of new synthesis, not the original seed virus carrying through to the final 
preparation. The infectious titer of RP6 and HEK293 cells were calculated, showing a clear 
difference in the amount of virus produced in each case (Figure 3-6C). The overall 
infectious titer of RP6 cells was lower than the Pf3 producer cells of Figure 3-1. Possible 
causes may have been insufficient dose of seed virus and/or integrated vector copy numbers. 
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Figure 3-6: Vector design and packaging clone characterization. (A) A synthetic rAAV 
packaging cell line and its two AAV genetic elements. GSTA denotes the GeneSwitch 
Transactivator gene; rtTA3 denotes the Reverse Tet Transactivator gene; CymR denotes 
the Cym Repressor; DD denotes the Destabilization Domain. (B) GFP fluorescence images 
of infectious titer assay cells transduced with rAAV2-GFP from packaging cell clone RP6 
or HEK293 cells. (C) Virus infectious titer of induced RP6 cells or HEK293 cells, 
measured by infectious titer assay cells. Data represents mean and standard deviation of 
cell counts from six images. Significance assessed by Welch’s t-test. ***p<10-5. 
Stable cell lines for rAAV production have been elusive for many years. Here we 
demonstrated the extensive use of synthetic biology in mammalian cells to achieve fully 
inducible production of complex recombinant virus particles. Low basal transcription and 
37 
high induced transcription was achieved, and opportunities still exist in boosting protein 
translation for higher vector titers. Independent control over replication and packaging 
modules enabled unprecedented manipulation over the vector full particle content. Stable 
cell lines are the ultimate goal for scalable manufacturing, and the present work exemplifies 





4 Summary and Concluding Remarks 
Gene therapy using rAAV vectors is a therapeutic modality that is generating much 
excitement due to clinical successes. In order to maintain the rate of growth of the field, 
vector manufacturing technology must advance to address the challenges associated with 
making a complex bio-nanoparticle product and assuring its potency and consistency. It 
was seen how various production and purification methods led to drastically different 
vector infectivities. Current methods of measuring infectious titer had very high inter-assay 
variability, which makes troubleshooting and process understanding difficult. Vector 
design and production platform also yield vectors with different full capsid ratios, but very 
little can be done to improve those ratios other than extensive downstream purification 
operations. These potential pitfalls must be addressed for the continued success of rAAV 
therapies. 
This thesis described a synthetic biology approach that led to two cell-based 
technologies which bear good news for the industry. The infectious titer assay cell line 
removed the need for helper virus coinfection, eliminating the bioreagent as a source of 
variability. And yet it performed comparably to the standard helper virus coinfection 
method, demonstrating its ability to promote second-strand synthesis and/or genome 
replication. The producer cell line integrated in full all the necessary components for rAAV 
synthesis. This makes feasible a cell line that can be grown to very large volumes and high 
densities. Infectious vectors were produced, and by varying the level of inducer molecules, 
the full capsid content was pushed to very high levels. The cells demonstrated the level of 
influence that can be exerted during rAAV production to adjust vector titer and quality. 
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Opportunities for further development of the technologies exist. Viral gene 
expression programs have specific dynamics that maximize their replicative potential. 
These can be studied by means of time-series transcriptomics and proteomics to determine 
the levels of viral factors at intervals post infection. The use of synthetic biology allows for 
the ability to mimic the transcript and protein expression profiles to achieve replication 
closer to a wild-type infection. But AAV genes are not the only available targets for 
optimization. AAV interacts with the host cell for control over cellular machinery. The 
ease of host cell genome engineering using technologies such as CRISPR/Cas9 allow 
knock out or activation of host cell factors which may restrict AAV replication. Finally, 
the cell culture environment is different from the natural environment that AAV would 
normally infect a host. That provides opportunities to study how the AAV replication and 
packaging processes are impacted by the cell culture conditions. Process parameters such 
as temperature, pH, and media formulation can have drastic impacts on cell physiology and 
metabolism. With the plentiful tools available for improvement, the future holds promise 
for rAAV vector production. 
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5 Addendum: Epigenomic features revealed by ATAC‐seq impact 
transgene expression in CHO cells 
Reproduced with permission from: Lee, Z., Raabe, M., and Hu, W. Epigenomic features 
revealed by ATAC-seq impact transgene expression in CHO cells. Biotechnology and 
Bioengineering. 2021; 118: 1851– 1861. https://doi.org/10.1002/bit.27701 
 
5.1 Summary 
Different regions of a mammalian genome have different accessibilities to transcriptional 
machinery. The integration site of a transgene affects how actively it is transcribed. Highly 
accessible genomic regions called super-enhancers were recently described as strong 
regulatory elements that shape cell identity. Super-enhancers were identified in Chinese 
Hamster Ovary (CHO) cells using Assay for Transposase-Accessible Chromatin 
Sequencing (ATAC-seq). Genes near super-enhancer regions had high transcript levels and 
were enriched for oncogenic signaling and proliferation functions, consistent with an 
immortalized phenotype. Inaccessible regions in the genome with low ATAC signal also 
had low transcriptional activity. Genes in inaccessible regions were enriched for remote 
tissue functions such as taste, smell, and neuronal activation. A lentiviral reporter 
integration assay showed integration into super-enhancer regions conferred higher reporter 
expression cells than insertion into inaccessible regions. Targeted integration of an IgG 
vector into the Plec super-enhancer region yielded clones that expressed the 
immunoglobulin light chain gene mostly in the top 20% of all transcripts with the majority 
in the top 5%. The results suggest the epigenomic landscape of CHO cells can guide the 
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selection of integration sites in the development of cell lines for therapeutic protein 
production. 
5.2 Introduction 
Since the dawn of recombinant biologics manufacturing, cell culture process titers 
have increased by several orders of magnitude. Much of that advance can be attributed to 
enhanced process engineering and high productivity of producing cell lines. To attain high 
productivity, the producing cell must express the transgene to a high transcript level and 
possess other cellular characteristics associated with high levels of protein secretion. These 
important traits must also be retained over a large number of cell divisions. High transcript 
levels of transgene have classically been achieved through co-amplification of a transgene 
and a selectable marker such as dihydrofolate reductase or glutamine synthetase (Kingston, 
Kaufman, Bebbington, & Rolfe, 2002). Yet the amplification process prolongs the timeline 
of cell line development and may introduce chromosomal aberrations (S. J. Kim & Lee, 
1999; Wurm & Wurm, 2017), increasing the risk of cell-line instability. Site-specific 
recombination using loxP/Cre (Kito, Itami, Fukano, Yamana, & Shibui, 2002), FRT/FLP 
(Huang et al., 2007), and att/Bxb1 (Inniss et al., 2017) hold promise to shorten the timeline 
of cell line development. These methods integrate transgenes into pre-established “landing 
pads” which may confer high transgene expression. With advances in genome engineering 
tools such as CRISPR/Cas9 (Cong et al., 2013), landing pads can be rationally chosen 
based on bioinformatic analysis.  
The integration location of a transgene affects its expression (Barnes, Bentley, & 
Dickson, 2003; Wallrath & Elgin, 1995). An ideal target integration site should have the 
local context that favors stable and highly active transcription. A class of potentially 
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favorable genomic neighborhoods is the super-enhancer. Super-enhancers are clusters of 
enhancers which were noted to have higher influence on transcription than regular 
enhancers (Sengupta & George, 2017; Thandapani, 2019). Many super-enhancers are 
associated with master regulator transcription factors that regulate the expression of genes 
in control of cell identity (Whyte et al., 2013). In cancer, increased expression of many 
oncogenes were attributed to super-enhancers which were not found in healthy tissues 
(Peng & Zhang, 2018; Sengupta & George, 2017). In some cases, the regulatory activity 
of super-enhancers can be co-opted to other genes via translocations in a process known as 
enhancer hijacking. Some examples include translocations of the MYC oncogene to both 
Ig-associated and non-Ig-associated super-enhancer loci (Walker et al., 2014), and the 
GFI1B oncogene to the BARHL1/DDX31 and PRRC2B super-enhancer loci (Northcott et 
al., 2014). Super-enhancers may have similar effects on transgenes that integrate in their 
region of influence. 
In contrast to highly active super-enhancers, other chromatin regions have 
repressive effects and may negatively affect the expression of integrated transgenes. The 
expression of the white transgene in Drosophila decreased when juxtaposed with 
heterochromatin (Wallrath & Elgin, 1995). Five distinct chromatin states were later 
described in Drosophila, with three states corresponding to traditional heterochromatin or 
repressive chromatin. These regions covered nearly three-quarters of the genome and had 
low transcriptional activity (Filion et al., 2010). These features pose a challenge to high 
transgene expression. 
Given the potential influence of epigenomic features on the expression of integrated 
transgenes, we sought to better characterize super-enhancers and inaccessible regions in 
43 
CHO cells. ATAC-seq has been used to identify super-enhancers (Semenkovich et al., 
2016). ATAC-seq offers a wide breadth of information by not focusing on a particular 
DNA binding protein, but rather capturing any event which displaces nucleosomes from 
DNA such as transcription factor binding and transcription initiation. ATAC involves 
relatively straight forward laboratory procedures and is easily accessible for many labs. 
Here, ATAC-seq was used to identify super-enhancers in CHO cells. Integrating transgenes 
near these loci and away from inaccessible regions has the potential to facilitate the 
construction of high producing cell lines of recombinant proteins. 
5.3 Materials and Methods 
5.3.1 Cell Culture 
CHO-K1 cells (ATCC CCL-61) and derived cells were cultured in Ham’s F-12K 
(Kaighn’s) Medium (Gibco) with 10% Fetal Bovine Serum (Gibco) at 37°C and 5% CO2. 
2C10 cells, an IgG producer with a single copy of IgG heavy and light chain genes 
integrated in its genome were previously established using lentiviral transduction (O'Brien 
et al., 2018). 
5.3.2 Next-gen Sequencing Analysis 
The ATAC transposition reaction as previously established (Buenrostro, Wu, 
Chang, & Greenleaf, 2015) was carried out on fifty-thousand cells in exponential growth 
phase. Transposed DNA was purified using a MinElute PCR cleanup kit (Qiagen). After 
library preparation, >50 million paired end reads were obtained by an Illumina HiSeq 2500 
instrument. Adapter sequences and low-quality base calls were trimmed using 
trimmomatic. Trimmed reads were mapped to the mitochondrial genome, then all 
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unmapped reads were mapped to the Cricetulus griseus genome (Vishwanathan et al., 2016) 
using Bowtie2 with parameters -N 1 -L 20 -i S,1,0.50 -D 20 -R 3 -I 38 -X 2000. 
Peaks were called using MACS2 with parameters: -p 0.00001 --nomodel --shift -
100 --extsize 200 --bdg. Peaks -1kb to +100bp of transcription start sites were excluded 
using HOMER. Neighboring peaks separated by less than 12.5kb were stitched together 
using Bedtools. Read coverage in stitched peaks was computed and background coverage 
from CHO-K1 whole genome sequencing (Xu et al., 2011) in the same region were 
subtracted to give the ATAC signal. Peaks were ranked by ATAC signal, the inflection 
point of the ATAC signal vs. rank curve was set as the cutoff, and the peaks above the 
cutoff were taken as super-enhancers (Whyte et al., 2013). Inaccessible regions were 
identified by using Bedtools complement which returned all genomic regions not covered 
by peaks, then filtering for those at least 100kb in size. 
RNA sequencing data was analyzed as previously described (O'Brien et al., 2018). 
5.3.3 Targeted Integration using CRISPR/Cas9 
Synthetic messenger RNA for eSpCas9(1.1) was in vitro transcribed using the 
mMESSAGE mMACHINE T7 Ultra kit (Invitrogen) and sgRNA was in vitro transcribed 
using the MEGAshortscript T7 Transcription kit (Invitrogen). RNA was purified using the 
MEGAclear Transcription Clean-Up kit (Invitrogen). Donor plasmids were constructed by 
Type IIs assembly of BFP/tk backbone vector, IgG-dGFP expression cassette, and two 
500bp homology arm gBlocks (Integrated DNA Technologies) using the SapI enzyme. 
CHO-K1 cells were electroporated with Cas9 mRNA, sgRNA, and donor plasmid using a 
Bio-Rad Gene Pulser XCell Electroporation system with 4mm cuvettes and the settings 
300V, 15ms, square wave. 
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Cells were passaged for two weeks to dilute out excess donor plasmid, and 
subsequently cells were sorted on a BD FACSAria II Cell Sorter with a 100μm nozzle. 
GFP-positive, BFP-negative cells were sorted into 96-well plates at one cell per well. After 
four days, the cells were treated with 80μM ganciclovir for HSVtk-mediated killing. Cells 
were expanded and assayed for expression of IgG mRNA using the Cells-to-CT 1-Step 
Power SYBR Green kit (Invitrogen). 
5.4 Results 
5.4.1 Super-enhancers identified by ATAC-seq 
ATAC-seq was performed on CHO-K1 and 2C10, a CHO-K1-derived single-copy 
IgG producer (O'Brien et al., 2018). ATAC-seq peaks were stitched and rank-listed by 
background-subtracted read coverage to give ATAC signal. The stitched peaks separated 
into two regions: a small subset with rapidly rising ATAC signal and a large subset of 
relatively low signal (Figure 5-1A). Those with signal higher than the inflection point in 
the curve were considered to be putative super-enhancers, (Whyte et al., 2013) with 731 
and 1124 being identified for CHO-K1 and 2C10, respectively. The mean read coverage 
of the 50kb regions centered on super-enhancer regions was higher over a broad region 
than non-super-enhancer regions (Figure 5-1B). 
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Figure 5-1: Super-enhancers in CHO and their associated genes. (A) Stitched ATAC-seq 
peaks in CHO-K1 cells ranked by background-subtracted read coverage, given in reads per 
million (RPM). Points above the infection point indicate stitched peaks designated as 
super-enhancers. Selected genes associated with the super-enhancer peaks are labeled. (B) 
Mean ATAC-seq read coverage, calculated by averaging all reads per million per base pair 
(RPM/bp) in the 50kb windows centered on all super-enhancers or all non-super-enhancers. 
(C) Gene expression of super-enhancer associated genes, other enhancer associated genes, 
and all genes in CHO-K1. Whiskers extend 1.5 times the inter-quartile range, and “x” 
defines the mean. (D) Circular genome view plotting CHO-K1 and 2C10 super-enhancers 
within all C. griseus scaffolds greater than 100kb. Each numbered box represents a scaffold 
and each point represents a super-enhancer. 
The closest gene, including overlapping genes, were assigned to be associated with 
a super-enhancer. All other stitched peaks were considered as “other enhancers” and 
associated genes were assigned in the same way. Transcript abundance levels of genes 
associated with super-enhancers were higher than those of non-super-enhancer associated 
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genes or all genes (Figure 5-1C). Several functional classes were enriched among those 
super-enhancer associated genes, including signal transduction and cancer-related KEGG 
pathways (Table 5-1). Notable among those in the TNF signaling pathway were the 
upstream receptor Tnfrsf1b and downstream transcription factors Creb1, Creb3l1, and 
Atf6b. Similarly, in the PI3K-AKT signaling pathway, upstream receptors such as Igfr1, 
Itgav, and Itga7, signal transducers such as Pik3ca, and downstream cell cycle effectors 
such as Cdk6 and Myc were represented in the super-enhancer-associated gene set. 
Table 5-1: Selected significantly enriched KEGG pathways among super-enhancer 
associated genes in CHO-K1. 
KEGG Pathway p−value 
TNF signaling pathway 1.0e−03 
PI3K−Akt signaling pathway 1.1e−03 
Proteoglycans in cancer 2.3e−03 
Pathways in cancer 2.8e−03 
Insulin resistance 4.5e−03 
Endocytosis 8.6e−03 
 
5.4.2 Stability of super-enhancers through genetic lineages 
Similar to the CHO-K1 super-enhancers, the 2C10 super-enhancers had higher 
mean read coverage than other stitched peaks, while super-enhancer associated genes also 
had higher transcript levels than other enhancer associated genes (Figure 5-2). The 
normalized ATAC-signal of super-enhancers that were identified for CHO-K1 and 2C10 
were arranged in circular genome view (Figure 5-1D). All super-enhancer regions were 
represented as circles among all scaffolds greater than 100kb in length, with the size of the 
circle corresponding to the relative ATAC signal of that super-enhancer. A large proportion 
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of CHO-K1 and 2C10 super-enhancers localized to the same genomic regions, with 
similarly large circles coinciding in the same regions. 
 
Figure 5-2: Super-enhancers in 2C10 and comparison to CHO-K1. (A) Super-enhancers 
from CHO-K1 mapped to 2C10 stitched peaks. Of 731 CHO-K1 super-enhancers, 72.6% 
(531) are also called super-enhancers in 2C10. Furthermore, 90% of CHO-K1 super-
enhancers (658/731) are within the top 7.5% of 2C10 stitched peaks. (B) Mean ATAC-seq 
read coverage in the 50kb windows centered on all 2C10 super-enhancers or non-super-
enhancers. (C) Gene expression of super-enhancer associated genes, other enhancer 
associated genes, and all genes in 2C10. Whiskers extend 1.5 times the inter-quartile range, 
and “x” defines the mean.  
The majority of CHO-K1 super-enhancers (72.6%) were also identified as super-
enhancers in 2C10 (Figure 5-2). Those which were not identified as super-enhancers in 
2C10 fell mostly in the region immediately below super-enhancers (Figure 5-2). This 
finding suggested the stability of super-enhancers through cell lineages. 
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5.4.3 Inaccessible regions reveal genomic organization 
In addition to identifying super-enhancers and peaks in active chromatin, ATAC-
seq data also revealed regions of chromatin which were less accessible and likely not active. 
Regions between sequential peaks that were more than 100kb apart were considered 
inaccessible regions. An example of inaccessibility was the long stretch of genome 
(2.5Mbp) surrounding the Dcc gene that was devoid of peaks between Mbd2 and Mex3c 
(Figure 5-3A). The CHO-K1 RNA-seq coverage shown in Figure 2A demonstrated the 
transcriptional activity of the flanking genes Mbd2 and Mex3c. However, the Dcc and gene, 
which encodes a netrin 1 receptor for axon guidance of neurons and tumor suppression had 
very low transcriptional activity. 
 
Figure 5-3: Inaccessible Regions in CHO-K1 and their associated genes.(A) Local genome 
view of representative inaccessible regions near the Dcc gene. (B) Length distributions of 
super-enhancers and inaccessible regions. (C) Proportion of the CHO genome covered by 
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super-enhancers and inaccessible regions. (D) Density plot of expression for genes 
associated with super-enhancers, inaccessible regions, or neither. 
The length of super-enhancers spanned over 500-fold but rarely extended beyond 
100kb (Figure 5-3B). In contrast, some inaccessible regions extended upwards of 1Mb. A 
large proportion of inaccessible regions were near 100kb. The choice of length criterion 
for calling inaccessibility thus affected the number of inaccessible regions in the genome. 
Using 100kb as the criterion, the inaccessible regions covered more than half of the genome, 
while super-enhancers represented a select subset of the genome (Figure 5-3C). If the 
criterion was set at 300kb, the proportion of the genome that was inaccessible was still over 
30% (data not shown). Inaccessible regions thus constitute a very large fraction of the entire 
genome. 
The genes in the inaccessible regions were significantly enriched for tissue-specific 
KEGG pathways such as sensory input and neuronal signaling (Table 5-2). Among the 
1175 genes annotated in the KEGG olfactory transduction pathway, 914 were identified to 
be within inaccessible regions. Within the neuroactive ligand-receptor interaction pathway, 
inaccessible regions represented genes such as GABA receptor subunits Gabra4 through 
Gabra6, histamine receptors Hrh1 and Hrh4, and dopamine receptor Drd2, all of which 
had 0 TPM according to RNA-seq analysis. 
Table 5-2: Selected significantly enriched KEGG pathways among genes in CHO-K1 
inaccessible regions. 
KEGG Pathway p−value 
Olfactory transduction < 2.3e−308 
Type I diabetes mellitus 1.3e−05 





Taste transduction 2.5e−04 
Retinol metabolism 5.6e−04 
 
5.4.4 Impact of accessibility on the transcriptome 
Since mRNA abundance is a balance between transcription and RNA turnover rate, 
the transcript level may not directly reflect the transcription rate. Nevertheless, the majority 
(74%) of super-enhancer associated genes were expressed above the median expression of 
all genes (Figure 5-3D). Compared to genes which were neither associated with super-
enhancers nor inaccessible regions, super-enhancer associated genes had lower frequency 
in the non-expressed region and higher frequency in the highly expressed region. In 
contrast, the majority of genes within inaccessible regions had transcript levels below one 
tenth of the median level of all genes (0.5 TPM). However, 15% had expression levels 
higher than the median of all genes, while a small portion were expressed at high levels (> 
5 TPM), including Ghitm and Lta4h. If regions with low RNA-seq read density or length 
greater than 300kb were used as the criterion, the resulting inaccessible regions had much 
fewer transcriptionally active genes (Figure 5-4). However, this also failed to identify many 




Figure 5-4: The number of genes associated with inaccessible regions. Binning was 
performed by transcript expression level as measured by RNA-seq TPM. When the 
originally defined inaccessible regions are filtered for RNA-seq read density in the region 
less than 0.1 times the genome-wide average or length greater than 300kb, fewer expressed 
genes are found but also fewer non-expressed genes are found. 
 
5.4.5 Accessibility of Integration Sites of Transgene 
In a previous study (O'Brien et al., 2018), a reporter gene (GFP) in a lentivirus 
vector was integrated at MOI of <=0.02 to isolate low-copy integrants. Through FACS the 
bottom 10% and top 1% GFP-expressing cells were pooled and integration sites were 
identified using PacBio sequencing. In addition, 34 top 1% single-copy clones were 
isolated and integration sites assessed by traditional Sanger sequencing of vector-genome 
junctions. The accessibilities of their integration sites were evaluated. Of these 34 clones, 
four had their integration sites in or within 50kb of a super-enhancer (Figure 5-5A). The 
integration sites of the top 1% pool showed a marginally higher representation near super-
enhancers than the bottom 10% pool and a random sampling of 10,000 genomic regions, 
while the top 1% single-copy clones showed significant enrichment for super-enhancer 
regions compared to those populations (Table 5-3). 
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Figure 5-5: Intersecting integration site data with epigenomic features. Integration sites of 
randomly integrated GFP transgene tested for whether they are (A) within 50kb of a super-
enhancer or (B) overlap an inaccessible region. Frequencies were compared pairwise using 
the 2x2 Boschloo’s one-tailed exact test. (C) A local genome view of a region which had 
six distinct integration events (red lines) among the bottom 10% population. *p<0.05, 
**p<0.01, ***p<1e-5. 
Table 5-3: Significance of pair-wise comparisons of lentiviral integration sites within 50kb 
of a super-enhancer. The p-values calculated via pair-wise Boschloo one-tailed exact tests. 
*p<0.05, **p<0.01. 
 Bottom10% Random Top1% Top1%Clones 
Bottom10%  0.16 0.079 0.0086** 
Random   0.16 0.018* 
Top1%    0.065 
Top1%Clones     
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Only eight out of the 34 top 1% single-copy clones were found to be associated 
with inaccessible regions (Figure 5-5B). One of the eight had a very low regional RNA-
seq read coverage (< 0.1 times the genome-wide average) near the integration site and had 
the lowest level of GFP transcripts among all clones, making it most likely a mis-sorted 
clone in FACS operation. In the remaining seven top 1% clone integration sites, the 
associated inaccessible regions overlapped transcriptionally active genes. Most of these 
genes were extremely long (> 95kb) with an ATAC peak at the transcription start site, but 
with long intragenic regions without peaks. This partially explained why these were 
identified as inaccessible regions. In comparison, over half of the integration sites of the 
bottom 10% pool were in inaccessible regions, a level comparable to that of random sites 
and significantly higher than that of the top 1% pool or the top 1% single-copy clones 
(Figure 5-5B and Table 5-4). 
Table 5-4: Significance of pair-wise comparisons of lentiviral integration sites in 
inaccessible regions. The p-values calculated via pair-wise Boschloo one-tailed exact tests. 
*p<0.05, **p<0.01, ***p<1e-5. 
 Bottom10% Random Top1% Top1%Clones 
Bottom10%  1.4e−01 1.8e−08*** 4.2e−06*** 
Random   5.4e−12*** 9.1e−06*** 
Top1%    3.3e−02* 
Top1%Clones     
 
Interestingly, a 2Mb stretch of inaccessible regions harbored six distinct integration 
events from the bottom 10% pool, suggesting that certain genomic locations were 
especially poor sites for exogenous gene expression (Figure 5-5C). No top 1% pool or 
clone integration events were detected in this region. 
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5.4.6 Site-directed integration into one super-enhancer 
The data presented above indicated that product genes integrated near super-
enhancer regions were more likely to have high transcript levels. Thus, the ideal candidate 
for site-directed gene integration should be a super-enhancer in the top tier of 
transcriptional activity (Figure 5-6A). Additionally, it should be a super-enhancer in both 
CHO-K1 and 2C10, and have no evidence of genomic instability as assayed by 
comparative genomic hybridization (Bandyopadhyay et al., 2019). We chose a super-
enhancer region that met these criteria and was among the top 1% GFP-expressing single 
copy clones’ integration sites. The region included the Plec gene (Figure 5-6B). An IgG 
expression construct was built for CRISPR-mediated integration with destabilized GFP as 
a positive selection marker as described previously (O'Brien et al., 2018). To reduce 
capturing random integration events, BFP and HSVtk were included in the backbone as 
negative selection markers (see Table 5-5). Integration was targeted to two loci: one 
proximal to the super-enhancer (sites A and B) in the same vicinity as a single-copy clone, 
the other 50kb from the opposite end of the super-enhancer (sites C and D). In each locus, 
the transgene cassette was integrated in both directions. 
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Figure 5-6: CRISPR-mediated integration into putative super-enhancer site. (A) The 
approach taken to select the super-enhancer for testing. (B) The gene construct and 
integration orientations around the Plec super-enhancer site. The “B” orientation matches 
one single-copy GFP clone identified in the lentiviral integration screen. (C) The transcript 
abundance of IgG light chain in the lentiviral integration sub-pools and the site-specific 
integration sub-pools. (D) The overall RNA-seq distribution of non-zero-TPM genes in the 
CHO-K1 transcriptome. The qRT-PCR expression level of all isolated clones was 
converted to TPM using Gapdh as a common reference. 
Table 5-5: Clone selection statistics. The number of isolated clones from fluorescence-
activated cell sorting and subsequent number of clones which passed further selection and 
screening during integration into the Plec super-enhancer region. 
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 Number of Clones % of Parent 
BFP-negative, isolated 186 NA 
   GCV-resistant 136 73 
      Assayed by Junction PCR 92 68 
         Correct Junctions 69 75 
 
Upon CRISPR-mediated transgene integration, GFP-expressing cells were FACS-
sorted into single-cell clones or pools. The GFP-expressing cell pool from integration site 
B and the top 10% subset of that pool were assayed for IgG light chain transcript level by 
qRT-PCR (Figure 5-6C). The light and heavy chain transcripts from this expression 
cassette were previously shown to be similar (O'Brien et al., 2018). The light chain 
transcript level was also correlated to GFP fluorescence intensity (Figure 5-7). Transcript 
levels of the top 10% GFP-expressing cell pool was comparable to the top 10% pool 
obtained via lentiviral random integration described above. The IgG light chain transcript 
levels in the 69 clones across the four integration sites (denoted by color) were denoted on 
the transcript abundance distribution curve (Figure 5-6D). Except for seven clones, all were 
in the top 20% abundance level of expressed cellular transcripts. Most clones also 
possessed higher light chain transcript abundance than Plec, the gene overlapping the 
super-enhancer. More than half were in the top 5% of expressed transcripts. As a reference, 
the expression level of Gapdh, one of the most abundant genes in CHO cells and a 
commonly used reference gene, was also marked. Most clones expressed light chain within 
a range between 2-fold higher to 8-fold lower than Gapdh (Figure 5-6D), demonstrating 
that integrating near a super-enhancer can yield high transcription of transgene. However, 
the resulting clones still exhibited transcript levels spanning one order of magnitude in 
range. GFP expression of five representative clones was assessed after 50 generations of 
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culture and persistent high GFP expression was seen in all clones. The number of clones 
examined was small, but nevertheless the apparent stability was consistent with the finding 
that super-enhancers were stable through cell lineages (Figure 5-2). 
 
Figure 5-7: The relationship between GFP fluorescence to IgG light chain transcript level 
in targeted integration clones. Pearson’s correlation value is represented by r. The GFP 
relative fluorescence units (RFU) measurements were taken using a BioTek Synergy H1 
microplate reader, and the light chain transcript level was assessed by qRT-PCR. 
5.5 Discussion 
5.5.1 Super-enhancers and Inaccessible Regions Influence Cell Identity 
In this study we used ATAC-seq to identify super-enhancers comprised of clusters 
of highly accessible open chromatin peaks in CHO cells. Most super-enhancer-associated 
genes had higher transcript levels than the median of all genes with functional enrichment 
in signal transduction and cancer-related pathways. This may hint that the immortalization 
of CHO cells may involve super-enhancer-mediated upregulation of oncogenes in addition 
to the reported mutations in p53 (Vishwanathan et al., 2015) and amplification of cMyc 
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(Vishwanathan et al., 2017). Similar super-enhancer interactions with oncogenes have been 
reported in cancers such as multiple myeloma (Loven et al., 2013), triple-negative breast 
cancer (Wang et al., 2015), and medulloblastoma (Lin et al., 2016), among others. 
Comparison of CHO-K1 and a derived IgG-producing cell line 2C10 showed that 
super-enhancers can be stably inherited for a large number of cell divisions. A recent 
computational study analyzed 200 cell types to identify the core transcription factors which 
establish cell-type identity (D'Alessio et al., 2015). Among the top ten core transcription 
factors attributed to human immortalized ovary epithelium tissues, eight were mappable to 
the CHO genome, and three (E2f7, Ets1, Fosl1) were proximal to super-enhancers in CHO-
K1. Another two (Stat1, Hmga1) were found among the top 8% of CHO-K1 stitched peaks, 
immediately below the inflection point. All of these transcription factors are involved in 
regulation of cell proliferation and likely to be important for maintaining the immortalized 
phenotype. Super-enhancer analysis was also performed on Chinese hamster induced 
pluripotent stem cells (Pei et al., 2017) and the Sox2 and Klf4 pluripotency genes were 
found to be associated with super-enhancers (data not shown). This supports the idea that 
super-enhancers contribute to maintaining specific cell phenotypes and are epigenetically 
stable in a cell line. 
In contrast to super-enhancers, inaccessible regions with long stretches of genome 
without any ATAC-seq peaks were rich in silent genes specific to tissues such as the 
neuronal and sensory organs. These results were consistent with previous reports which 
found genes without accessible promoters were enriched for tissue-specific genes such as 
rhodopsin-like receptors and olfactory receptors (Boyle et al., 2008). Important to 
establishing the identity of a cell type is not only the expression of genes associated with 
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the cell type, but also the suppression of genes specific to other cell types through 
inaccessibility of chromatin. These regions were also found to be stably inherited through 
many cell divisions as 97% of inaccessible regions in the 2C10 cell line overlapped 
inaccessible regions in CHO-K1 (data not shown). 
Before ATAC became commonly used, studies aimed at annotating the epigenome 
employed ChIP-seq or DNase-seq to cluster genome regions into distinct chromatin states. 
One study classified large proportions of the genome as repressed, with low gene 
expression levels and higher frequencies of transgene silencing when a gene is inserted into 
these regions (Filion et al., 2010). Another study described quiescent-state chromatin as 
devoid of transcription and transcription factor binding (Hoffman et al., 2013). Both studies 
also reported these inactive regions to be longer than active areas. Here, we used a single 
assay, ATAC-seq, to identify inaccessible regions which shared similar characteristics with 
the described repressed and quiescent chromatin states. Given that only about half of the 
genes encoded in a mammalian genome are expressed in a given cell type, it is not 
surprising that at least half of the genome in CHO would be inaccessible. 
5.5.2 Integration site accessibility and GFP expression 
Random integration of a GFP- lentiviral vector revealed that the top 1% of GFP 
expressing clones had significantly higher frequencies of integration into super-enhancer 
regions. Though super-enhancers constituted only about 0.49% of the entire genome, 12% 
of the top 1% clones integrated into super-enhancer regions. It suggests a higher propensity 
of these regions to promote high transcriptional activity. The top 1% single-copy clones 
showed even greater enrichment for super-enhancers than the top 1% pool likely because 
the pool harbored “passenger” integration events in addition to integration in super-
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enhancer regions. During top 1% clone screening, 46% of clones were found to be 
multiple-copy, reflecting the frequency of multiple-copy integrations in the top 1% pool. 
About 60% of random integrants as well as those in the bottom 10% of GFP intensity had 
the vector integrated into an inaccessible region, significantly higher than those in the top 
1%. The results indicate that integration into accessible or inaccessible regions affects the 
chance of expression but does not guarantee high or low reporter activity. 
5.5.3 Comparison of super-enhancers to hot-spots and safe-harbors 
There has been a heightened interest in targeting integration into a specific genomic 
locus for transgene expression. The desired target site should promote a high level of 
transcription and confer long-term structural and gene expression stability. One study 
identified the Fer1L4 gene as a “hot-spot” in the genome through screening and targeted a 
product gene to the site (Zhang et al., 2015). Multiple studies targeted transgene integration 
into the glycosylation chaperone COSMC gene as a “safe-harbor” site for consistent and 
stable expression (J. S. Lee, Kallehauge, Pedersen, & Kildegaard, 2015; Ronda et al., 2014). 
These two sites were not among the CHO-K1 super-enhancers identified in this study, nor 
were they in inaccessible regions. Yet both sites were in genomic neighborhoods with high 
density of ATAC peaks and transcriptionally active genes. This further demonstrates that 
being in a super enhancer site increases the probability of high transcriptional activity, but 
it is not a necessary condition.  
Integration into the Plec super-enhancer resulted in over half of clones expressing 
the transgene at high levels—in the top 5% of all expressed cellular genes (Figure 5-3D). 
But even with a strong CMV promoter the expression level was not universally higher than 
that of a highly abundant housekeeping gene, Gapdh. In Drosophila some clusters of 
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multiple enhancers were ascribed to ensure a gene was expressed, but not necessarily to a 
very high level of expression (Perry, Boettiger, & Levine, 2011). This is consistent with 
the results shown in Figure 5-3D, where most genes are expressed at high but not 
necessarily at the highest levels. It has been reported that integration of a transgene into a 
predisposed transcriptionally active site identified in a high producer was highly active but 
could still be further enhanced by integrating two copies of the transgene into the same site 
(J. Carver et al., 2020). 
5.5.4 Variability of transcript level in clones integrated in super-enhancer regions 
It was reported that CRISPR-mediated integration of mCherry into CHO cells led 
to a more narrow range of fluorescence than clones created through random integration (J. 
S. Lee et al., 2015). In contrast, another study showed targeted integration of IgG resulted 
in clones with variable expression levels (J. Carver et al., 2020). Although most clones 
integrated near the Plec super-enhancer locus had high transcript levels of IgG, the 
expression level did span over a range. A number of factors could have caused the 
variability in the transcript levels. There are likely two alleles of the Plec gene in the CHO 
genome that may harbor some differences. The CMV promoter is often methylated which 
affects its transcriptional activity (M. Kim, O'Callaghan, Droms, & James, 2011; Moritz, 
Becker, & Gopfert, 2015). The CHO genome is inherently susceptible to karyotypic 
changes (Bandyopadhyay et al., 2019) resulting in a heterogeneous population that may 
also contribute to transcriptional activity variation.  
Despite integration in the vicinity of the Plec super-enhancer, the IgG titer 
measured during clonal expansion showed a range of distribution among the clones; some 
were similar to or even higher than the producing clone 2C10, while others were lower 
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(Figure 5-8). This titer distribution reminds us that the overall productivity is determined 
by a myriad of factors. A high level of transcription is just one component of a high 
producer cell line. Other traits are also important, including translation, protein folding, 
mitochondrial activity and biogenesis (Nissom et al., 2006), metabolism, protein secretion, 
redox balance, and growth/death control (Seth, Charaniya, Wlaschin, & Hu, 2007). 
Integration to a super-enhancer site facilitates accomplishing the critical role of high 
transgene transcript level. It is still beneficial to screen the resulting clones to isolate the 
highest producers which possess the additional traits of hyper-productivity. 
 
Figure 5-8: The distribution of IgG titer among Plec-targeted integration clones. Cells were 
split at a 1:6 ratio into a 24-well plate with 0.5 mL media. Supernatant was harvested on 
day three. Supernatant was diluted 1:400 and assayed by ELISA. The dotted vertical line 
represents the average titer of 2C10 assayed the same way. Several clones showed similar 
or greater titer to 2C10, a top 1% FACS-sorted cell line reported to have a specific 
productivity of 18 pg/cell/day (O'Brien et al., 2018).  
5.5.5 Concluding remarks 
Using ATAC-seq to identify super-enhancers and inaccessible regions in the CHO 
genome can facilitate the design or screening of cell lines for transgene expression. When 
random integration is used, the integration site can be identified by integration site analysis 
(O'Brien, Ojha, Wu, & Hu, 2020), and then ATAC-determined accessibility information 
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can be used in the selection of a production clone. Random integration methods have a 
high likelihood of inserting transgenes into inaccessible regions, which cover over half of 
the genome, leading to poor expression. Simply avoiding inaccessible regions may greatly 
narrow down the pool of candidate high-producers. Further, transgene integration into a 
super-enhancer region increases the probability of having high transcript expression. Since 
super-enhancers are epigenetically stable through cell lineages, integration into a super-
enhancer region can possibly confer long-term gene expression stability. Simultaneous 
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